Difference between revisions of "Motixafortide (Aphexda)"
Jump to navigation
Jump to search
m |
m |
||
| Line 1: | Line 1: | ||
cyclic-peptide CXCR4 inhibitor | cyclic-peptide CXCR4 inhibitor | ||
| + | |||
| + | ==History of changes in FDA indication== | ||
| + | *2023-09-12: Approved for the mobilization of hematopoietic stem cells to peripheral blood prior to collection for autologous stem cell transplantation (ASCT) in patients with multiple myeloma. ''(Based on GENESIS)'' | ||
| + | |||
| + | ==Also known as== | ||
| + | *'''Brand name:''' Aphexda | ||
[[Category:Drugs]] | [[Category:Drugs]] | ||
Revision as of 11:04, 31 October 2023
cyclic-peptide CXCR4 inhibitor
History of changes in FDA indication
- 2023-09-12: Approved for the mobilization of hematopoietic stem cells to peripheral blood prior to collection for autologous stem cell transplantation (ASCT) in patients with multiple myeloma. (Based on GENESIS)
Also known as
- Brand name: Aphexda